BIM-23190 is a synthetic peptide analog used to probe receptor-specific binding and conformational changes within targeted signaling pathways. The sequence contains hydrophobic and charged residues influencing secondary structure. Researchers employ it to dissect ligand architecture and binding kinetics. Its stability supports extensive biophysical evaluation.
CAT No: PI-008
CAS No:182153-96-4
Synonyms/Alias:BIM-23190;182153-96-4;BIM 23190;V55PUY46VR;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-7-ethyl-19-[[(2R)-2-[[2-[4-(2-hydroxyethyl)piperazin-1-yl]acetyl]amino]-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide;L-THREONINAMIDE, N-(2-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)ACETYL)-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-(2S)-2-AMINOBUTANOYL-L-CYSTEINYL-, CYCLIC (2->7)-DISULFIDE;BDBM85051;HY-P3124;CS-0146506;L-Threoninamide, N-((4-(2-hydroxyethyl)-1-piperazinyl)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2-7)-disulfide;L-Threoninamide, N-((4-(2-hydroxyethyl)-1-piperazinyl)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-2-aminobutanoyl-L-cysteinyl-, cyclic (2-7)-disulfide;L-Threoninamide, N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2-->7)-disulfide;N-(N'-(2-hydroxyethyl)-piperazinyl)-2-acetyl-Phe-Cys-Tyr-Trp-Lys-Abu-Cys-Thr-NH2 disulfide;N-(N'-(2-hydroxyethyl)piperazinyl)-2-acetyl-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-2-aminobutanoyl-cysteinyl-threoninamide disulfide;
Chemical Name:(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-7-ethyl-19-[[(2R)-2-[[2-[4-(2-hydroxyethyl)piperazin-1-yl]acetyl]amino]-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
BIM-23190 is a synthetic peptide analog recognized for its potent activity as a somatostatin receptor agonist, specifically targeting somatostatin receptor subtypes sst2 and sst5. As a member of the peptide compound category, it is structurally engineered to mimic the biological functions of native somatostatin, a regulatory neuropeptide involved in modulating hormone secretion and neurotransmission. The high receptor selectivity and stability of BIM-23190 make it a valuable molecular tool for dissecting somatostatin-mediated pathways in cellular and physiological models. Its use in research supports advanced investigations into neuroendocrine regulation, signal transduction, and receptor pharmacology.
Receptor Pharmacology Studies: As a selective somatostatin receptor agonist, BIM-23190 is widely employed in receptor binding and signaling assays to elucidate the pharmacological profiles of sst2 and sst5 subtypes. Researchers utilize this peptide to characterize receptor-ligand interactions, map receptor distribution, and investigate downstream signaling cascades. Its high affinity and specificity enable precise modulation of somatostatin pathways, facilitating the study of receptor function in both native tissues and recombinant expression systems.
Neuroendocrine Research: The compound serves as a critical tool for probing the regulatory mechanisms governing hormone secretion within the neuroendocrine axis. By activating somatostatin receptors, it enables researchers to model the inhibitory effects of somatostatin on the release of pituitary and pancreatic hormones such as growth hormone, insulin, and glucagon. This application is particularly relevant for studies examining feedback loops, hormone dynamics, and the modulation of endocrine cell activity in vitro and ex vivo.
Signal Transduction Analysis: BIM-23190 is instrumental in dissecting intracellular signaling pathways activated by somatostatin receptor engagement. Its use allows for the investigation of G protein-coupled receptor (GPCR) signaling events, including the regulation of cyclic AMP levels, calcium mobilization, and kinase activation. Such studies provide insights into the molecular mechanisms underlying receptor-mediated inhibition of cellular activity and contribute to the broader understanding of GPCR biology.
Peptide Structure-Activity Relationship (SAR) Studies: As a synthetic analog with defined receptor selectivity, BIM-23190 is frequently incorporated into SAR analyses aimed at optimizing peptide ligands for somatostatin receptors. Researchers leverage its structural features to compare functional activity, binding affinity, and metabolic stability relative to other analogs and the endogenous peptide. These investigations support the rational design of novel peptide therapeutics and molecular probes targeting the somatostatin system.
Peptide-Based Assay Development: The stability and specificity of BIM-23190 make it suitable for developing and validating bioassays that measure somatostatin receptor activation, hormone secretion, or signal transduction endpoints. Its predictable pharmacological profile enables the establishment of robust experimental platforms for screening receptor modulators, quantifying functional responses, and standardizing assay conditions in both academic and industrial research settings.
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
2. Emu oil in combination with other active ingredients for treating skin imperfections
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More